No-spa tablets of 40 mg blister pack of 24 pcs

Antispasmodic agents affect smooth muscles and eliminate pain caused by spasm. Antispasmodic drotaverine is used in gastroenterology, therapy, urology and gynecology in many countries of the world.

• Gastroenterology. In this area, the drug is prescribed for spastic pain accompanying biliary tract pathology – gallstone disease, acute or chronic cholecystitis, cholangitis, etc.
• Urology. Inflammatory processes in the urinary organs (cystitis, pyelitis) can also lead to spasms, so the use of drotaverin in these diseases is fully justified.
• Tension headaches. Drotaverin can also be used to treat tension headaches, as in this case there are muscular and vascular components.

The favorable safety profile has been confirmed by numerous clinical studies.

Spasms of smooth muscles associated with diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis.

Spasms of smooth muscles in diseases of the urinary tract: nephrolithiasis, urethrolithiasis, pyelitis, cystitis, bladder tenesmus.

• with spasms of the smooth muscles of the gastrointestinal tract: peptic ulcer disease of the stomach and duodenum, gastritis, cardio- and / or pyloric spasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome accompanied by flatulence;
• tension headache;
• with gynecological diseases: dysmenorrhea.

Hypersensitivity to drotaverine or any component of the drug. Severe liver, kidney or heart failure (low cardiac output syndrome).

Adults: the usual average dose is 120-240 mg per day in 2-3 doses.

For children aged 6-12 years: the maximum daily dose is 80 mg (divided into 2 doses).

For children older than 12 years: the maximum daily dose is 160 mg (divided into 2-4 doses).

Children

The use of the drug is contraindicated for children under 6 years of age.

The use of drotaverine in children has not been evaluated in clinical studies.

Use during pregnancy or breastfeeding

Pregnancy. The results of retrospective clinical studies showed that oral use of the drug did not cause any signs of any direct or indirect effect on pregnancy. However, it is necessary to prescribe the drug to pregnant women with caution.

Breast feeding. Due to the lack of data during breastfeeding, the use of the drug is not recommended.

Active substance: drotaverine; 1 tablet contains drotaverine hydrochloride 40 mg.

Excipients: magnesium stearate, talc, povidone, corn starch, lactose.

Keep out of the reach of children.

Store in the original packaging at a temperature below 25 °C.